Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
Akebia和CSL Vifor已終止許可協議，該協議規定Akebia在Vafseo（Vadadustat）美國淨產品銷售額上向CSL Vifor支付特許權使用費。結果，Akebia重新獲得了在美國出售Vafseo的全部權利。
- Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million.
- Announced Vafseo WAC pricing of $1,278 for a 30-day supply
- Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025
- 根據協議條款，CSL Vifor有權獲得季度分級特許權使用費，從高達4.5億美元的年淨銷售額的個位數百分比到超過4.5億美元的年淨銷售額的中等個位數百分比不等。Akebia有機會從2027年7月1日開始購買特許權使用費協議，向CSL Vifor一次性付款，這將使特許權使用費減少到AkebiaVafseo年度淨銷售額的中等個位數百分比，最高爲4.5億美元，並取消年淨銷售額超過4.5億美元的特許權使用費。
- 宣佈Vafseo WAC的30天供應定價爲1,278美元
- 2024 年 6 月提交了 Vafseo 的 TDAPA 申請，預計將於 2025 年 1 月 1 日獲得指定
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。